Inclusion Criteria:  Patients aged 18 years old or more Histologically proven invasive breast cancer Any T stage, any N Stage with no distant metastasis M0 as evident by clinical examination and sonomammography. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 2. Patients with Her-2 positive Luminal B subtype, Her-2 enriched or triple negative breast cancer. Patients who completed their systemic neoadjuvant therapy.  Exclusion Criteria:  Second malignancy Patients with early breast cancer clinicallyT1 (≤ 2 cm) N0 Metastatic patients M1 Patients with autoimmune diseases (Type I Diabetes mellitus, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjogren's syndrome and Behcet disease) Patients on systemic steroids or other immunomodulators (as Methotrexate, Tacrolimus and Cyclosporine) Patients who started but didn't complete neoadjuvant systemic therapy Patients who didn't undergo surgery after neoadjuvant systemic therapy